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Background: Peripheral artery disease affects 8–18 million people in the United States. Patients with peripheral
artery disease are known to have increased morbidity and mortality. Medical guidelines recognize ankle-brachial
index testing as an effective screening tool that allows for early detection of this disease in primary care settings.
Doppler ankle-brachial index, the standard method used, is time consuming and requires technical expertise.
Automated (digital) ankle-brachial index testing through plethysmography may be a more attractive method in
primary care settings due to its speed and ease of use. This observational study evaluated the use of one digital
ankle-brachial index device in primary care settings to describe the population tested and the results obtained.
Results: A total of 19 medical practices throughout the United States provided data on 632 patient tests. In the
population tested, the mean age was 67.2 (±13.8) years, and 38% of patients were male. Additionally, 94.7% of the
population had risk factors, signs and/or symptoms suspicious for peripheral artery disease, and 20.3% presented
with claudication. Twelve percent (76/632) of patient tests showed an abnormal digital ankle-brachial index (<0.93),
indicating a result positive for peripheral artery disease; the frequency of hypercholesterolemia, hypertension, and
coronary artery disease in this group was 62% (45/73), 69% (50/72) and 46% (34/74), respectively.
Conclusion: The results of this study support the use of a digital ankle-brachial index device using blood volume
plethysmography technology for evaluation of peripheral artery disease. Data is consistent with previously reported
population characteristics with respect to peripheral artery disease prevalence, signs/symptoms, and risk factors. The
device used in this study enabled evaluation for peripheral artery disease in primary care settings and may allow for
early detection of the disease.
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Peripheral artery disease (PAD) affects between 8–18
million people in the United States [1].Patients with
PAD are known to have increased morbidity and mortal-
ity [2,3]. Progression of PAD directly results in claudica-
tion, impaired walking, and amputation. The incidence
of stroke, myocardial infarction, death or hospitalization is
over 20% for patients with PAD [4]. Numerous medical
guidelines recognize early detection of PAD as a critical
factor both for mitigating PAD progression and improving
risk management of cardiovascular disease [5-7].* Correspondence: tdiage@namsa.com
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reproduction in any medium, provided the orPAD is characterized by impaired blood flow in the
peripheral arteries due to atherosclerosis. Reduced blood
flow and endothelial dysfunction are significant contrib-
utors to the progression of this disease, and the body of
research on genetic factors involved is continually grow-
ing [8,9]. Impaired angiogenesis and decreased capillary
supply to skeletal muscle are seen in PAD and may be
related to the symptoms and reduced functionality expe-
rienced by these patients. A recent trial showed that
after participating in a supervised exercise training regi-
men, PAD patients experience an increase in microvas-
culature in the calf skeletal muscle (as measured by
capillary density) and subsequent improvement in exer-
cise capacity [10]. While possibly not the only mechan-
ism for improved functionality, this study suggests thetd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Types of participating clinical sites




General/Family practice 57.9% (11/19) 52.2% (349/632)
Podiatry practice 31.6% (6/19) 31.3% (198/632)
Other 10.5% (2/19) 13.4% (85/632)
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on the metabolic potential of working muscles in PAD
patients. Research on potential treatments based on
these mechanisms of action is ongoing, and early detec-
tion of PAD remains very important in the treatment
course of patients with this disease.
Ankle-brachial index (ABI) testing is recommended by
the US Preventative Services Task Force and American
College of Cardiology for evaluating patients at risk for
PAD [6,7]. ABI testing in primary care settings can pro-
vide early diagnosis of PAD, allowing for earlier treatment
[11-13]. There are several methods used to perform ABI
measurement, with Doppler ABI being most common.
However, adoption of Doppler-based ABI in primary
care is limited. Previous studies have reported barriers
to implementation, including the time required to con-
duct tests, the training needed, and the technical skills
required [12,14].
Automated ABI, either through oscilloscope or pleth-
ysmography, may be a more attractive option in primary
care settings. This method is faster and easier, while
maintaining accuracy [11,12]; clinical results comparing
alternative ABI methods to Doppler ABI have shown
concordance above 90% [15-18]. This study evaluated
the use of a specific plethysmography, or digital ABI, de-
vice in primary care settings to determine if results were
consistent with known PAD population characteristics.
Methods
A device-specific, voluntary data registry was created to
capture physician reported results on adult patients. A
standardized, self-administered questionnaire was used
to identify PAD signs, symptoms and cardiovascular risk
factors in patients presenting to primary care practices
(see Additional file 1). Patients with signs, symptoms
and/or risk factors for PAD were then tested with a
digital ABI device (FloChec™ manufactured by Semler
Scientific, Inc, Portland Oregon United States) to evalu-
ate flow obstruction in each lower extremity compared
to the corresponding upper extremity. All data was de-
identified. ABI results, PAD signs and symptoms, and
cardiovascular risk factors were recorded and input into
a central database for analysis.
The FloChec™ device is a blood volume plethysmogra-
phy technology that received Food and Drug Administra-
tion (FDA) clearance for commercial use in the United
States in 2010. The FloChec™ system consists of a sensor
coupled with an infrared light emitting diode (LED) within
a pulse-oximetry style clamp, and an attached portable
computer that runs proprietary software. Measurements
with FloChec™ are performed bilaterally on the lower and
upper extremities by placing the clamp on one digit of
each extremity in sequential fashion. During measure-
ment, the LED transmits light into the digit, and thesensor measures reflected/scattered light. The blood vol-
ume in the digit affects the amount of returning light, and
these blood volume waveforms are recorded and analyzed
by the device. Blood flow index (BFI), a measure of prox-
imal patency, is calculated by a proprietary algorithm for
each extremity. Comparison of BFI in the lower extremity
to BFI in the upper extremity produces the ratio known as
digital ABI. Four pulse waveforms, four blood flow indices,
and two ABI results are provided in a standard report for
each patient. A digital ABI result of <0.93 indicates the
presence of flow obstruction.
Binary variables were created for each sign, symptom,
or risk factor based on the corresponding questionnaire
response. A subject was considered to have claudication
if the response to question one was “no” and the re-
sponse to questions two and three was “yes”. Standard
summary statistics were calculated for study variables of
interest. For continuous variables, statistics included the
number of observations (N), mean, standard deviation,
and 95% confidence interval. Categorical variables were
summarized in frequency distributions. Prevalence odds
ratios with 95% confidence intervals were calculated for
each categorical variable of interest, comparing the PAD
positive group to the PAD negative group. A multivari-
ate regression examining the effect of risk factors, signs
and symptoms, sex, and age on ABI was conducted. To
identify important predictors, a step-wise selection pro-
cedure that included all possible predictors collected in
the study and all possible two-way interactions was
executed. Terms were allowed to enter the model with a
significance level ≤0.3 and were removed if they had a sig-
nificance level ≥0.1. Statistical analyses were conducted in
SAS version 9.3 (SAS Institute, Cary, N.C.), and graphics
were produced in R version 2.11.1. Because the technology
used in this study has been commercially cleared in the
US and only de-identified data was collected, ethics com-
mittee approval was not required.
Results
A total of 19 medical practices throughout the United
States examined 632 patients with the FloChec™ system.
Table 1 provides a summary of practice types that partic-
ipated. These patients were tested based on results of a
self-administered questionnaire that indicated risk fac-
tors, signs, and/or symptoms suspicious of PAD. Data
was provided on digital ABI results for all patients. Of
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more missing data fields. These patients were included
in analysis. The number of completed fields used in
each calculation is provided in the tables. Population
characteristics are provided in Table 2. The average age
of the population tested was 67.2±13.8 years, and 38.0%
of the population was male (95% CI 33.7%-42.3%). Of
the patients tested, 94.7% had risk factors, signs and/or
symptoms suspicious for PAD, and 20.3% (95% CI
17.1%-23.6%) presented with claudication.
Twelve percent (76/632) of patients had an abnormal
FloChec™ result (digital ABI <0.93). The frequency of ab-
normal left leg result, abnormal right leg result, and ab-
normal result for both legs was 4.9% (31), 2.8% (18), and
4.3% (27), respectively. Of those with digital ABI <0.93
(PAD positive group), the mean age was 68.2±12.9 years
and 47.1% (95% CI 35.2%-58.9%) were male. In this group,
hypercholesterolemia, hypertension, and coronary artery
disease (CAD) were reported in 61.6% (95% CI 50.5%-
72.8%), 69.4% (95% CI 58.8%-80.1%), and 45.9% (95% CI
34.6%-57.3%) of patients, respectively. A self-reported his-
tory of smoking was found in 50.7% (95% CI 39.4%-62.0%)
of the abnormal digital ABI patients. Figure 1 shows the
prevalence of positive PAD result by sex and age group.
Patients with digital ABI <0.93 were more likely to be in
age groups 60–69 and 70+ (28.9% and 48.7%, respectively)
than in age groups <50 and 50–59 (10.5% and 11.8%,
respectively).
Of the 122 patients with symptoms of claudication, 18
(14.8%) tested positive for flow obstruction on digital
ABI measurement while 54 (11.3%) of the patients with-
out claudication (asymptomatic) tested positive. There
was no difference observed in digital ABI value between
symptomatic and asymptomatic patients; the mean digital
ABI and standard deviation was 0.95±0.13 and 0.96±0.12
for those with claudication (N=122) and without claudica-
tion (N=478), respectively.
Table 3 displays prevalence odds ratios for each meas-
ure examined. Several risk factors were statistically sig-
nificantly more common in the PAD positive group
than the PAD negative group; these included smoking
history (OR 1.63, 95% CI 1.00-2.64), stroke/transient is-
chemic attack (TIA) (OR 2.70, 95% CI 1.51-4.85), and
CAD (OR 1.84, 95% CI 1.12-3.01). From the multivari-
ate analysis, two predictors, hypertension (p=0.018) and
stroke/TIA (p=0.0360), emerged as having the most in-
fluence on ABI.
Discussion
In this study, primary care practices evaluated patients
suspected to have PAD based on history and physical
exam and performed digital ABI measurements. Of these
patients, 12% were confirmed to have obstructed flow
based on the criteria of the digital ABI test. These resultsare similar to previous findings using other ABI methods.
Reported prevalence of PAD ranges from 4.3% to 16.8%;
with age adjusted prevalence of 12% [19-22]. Selvin and
Erlinger reported an overall frequency of 4.3%, with a sig-
nificant increase in prevalence among those 60–69 (4.7%)
and over 70 (14.5%) years old [22]. As depicted in
Figure 1, our study demonstrated similar trends, with
patients 60 years and older yielding the highest fre-
quency of obstructed flow. Characteristics of the pa-
tients with obstructed flow identified by digital ABI in
this study population were consistent with other PAD
studies with respect to mean age, proportion of males,
and positive limbs (right, left, or both) [19,20,22].
The prevalence of risk factors in patients with obstructed
flow measured by FloChec™ was consistent with previous
findings evaluating other techniques. Several studies, in-
cluding REACH (the largest international PAD registry
study conducted to date), report rates of hypercholesterol-
emia, hypertension, and diabetes (66.7%, 81.0% and 44.6%
respectively) similar to or higher than our findings (61.6%,
69.4% and 53.3%, respectively) [19]. Selvin and Erlinger
also reported similar rates (60.6%, 73.6% and 26.4%, re-
spectively) [22]. The prevalence of PAD in patients with
greater than three risk factors was also concurrent. This
study found 65.8% of patients with flow obstruction had
three or more risk factors, compared to 60-80% of popula-
tions previously studied [19,20,22].
Earlier accurate PAD diagnosis and treatment initiation
could potentially greatly improve clinical outcomes; as in-
dicated by Duscha et al., there is a growing body of re-
search around exercise training as therapeutic intervention
to promote angiogenesis of the microvasculature in the
lower extremity skeletal muscle and improve exercise toler-
ance [23]. Recent evidence also suggests that a particular
calcium/calmodulin-dependent kinase (CaMK4) may have
an important role in blood pressure regulation through the
control of endothelial nitric oxide synthase (eNOS) activity
via phosphorylative events. In this study, loss of the
CaMK4 gene resulted in endothelial dysfunction, hyperten-
sion, and related complications in mice. In humans, a
significant correlation was found between reduced expres-
sion of a CaMK4 polymorphism and higher blood pressure
levels among hypertensive patients [9]. Another study on
the in vivo effects of a vascular endothelial growth factor
(VEGF) mimetic (called QK) offered a potential new
method for examining angiogenesis triggered by VEGF re-
ceptors. The proteins involved are important for capillary
formation and organization and could have large implica-
tions for treatment of conditions like chronic ischemia [8].
While research on the etiologies and mechanisms of action
of PAD continues, our study supports correlations ob-
served between clinical manifestations and impaired blood
flow Figure 1. Interestingly, TIA/stroke (another clinical
outcome of endothelial dysfunction) was a statistically
Table 2 Summary of study population demographics, signs/symptoms, and risk factors
Measure All subjects PAD negative subjects PAD positive subjects
Mean ± SD (N)
95% CI
Mean ± SD (N)
95% CI
Mean ± SD (N)
95% CI
or or or
% (n/N) % (n/N) % (n/N)
Age (years) 67.2 ± 13.8 66.1, 68.3 67.1 ± 13.9 65.9, 68.2 68.2 ± 12.9 65.2, 71.1
(627) (551) (76)
Age group (years)
<50 10.7% 8.3%, 13.1% 10.7% 8.1%, 13.3% 10.5% 3.6%, 17.4%
(67/627) (59/551) (8/76)
50-59 17.7% 14.7%, 20.7% 18.5% 15.3%, 21.8% 11.8% 4.6%, 19.1%
(111/627) (102/551) (9/76)
60-69 25.5% 22.1%, 28.9% 25.0% 21.4%, 28.7% 28.9% 18.8%, 39.1%
(160/627) (138/551) (22/76)
70+ 46.1% 42.2%, 50.0% 45.7% 41.6%, 49.9% 48.7% 37.4%, 59.9%
(289/627) (252/551) (37/76)
Male 38.0% 33.7%, 42.3% 36.6% 32.0%, 41.1% 47.1% 35.2%, 58.9%
(190/500) (158/432) (32/68)
Claudication 20.3% 17.1%, 23.6% 19.7% 16.3%, 23.1% 25.0% 15.0%, 35.0%
(122/600) (104/528) (18/72)
Discolored/blue legs 21.6% 18.3%, 24.8% 20.6% 17.2%, 24.0% 28.4% 18.1%, 38.7%
(133/617) (112/543) (21/74)
Non-healing wound 11.4% 8.9%, 13.9% 11.0% 8.4%, 13.6% 14.5% 6.6%, 22.4%
(71/622) (60/546) (11/76)
At least 1 sign/symptom 42.1% 38.2%, 46.0% 41.2% 37.1%, 45.3% 48.7% 37.4%, 59.9%
(264/627) (227/551) (37/76)
High cholesterol 61.5% 57.6%, 65.3% 61.5% 57.3%, 65.6% 61.6% 50.5%, 72.8%
(375/610) (330/537) (45/73)
Hypertension 72.5% 69.0%, 76.1% 73.0% 69.2%, 76.7% 69.4% 58.8%, 80.1%
(444/612) (394/540) (50/72)
Diabetes 47.3% 43.4%, 51.3% 46.5% 42.3%, 50.7% 53.3% 42.0%, 64.6%
(291/615) (251/540) (40/75)
Smoking history 40.1% 36.3%, 44.0% 38.7% 34.6%, 42.8% 50.7% 39.4%, 62.0%
(250/623) (212/548) (38/75)
Stroke/TIA 13.2% 10.6%, 15.9% 11.5% 8.8%, 14.2% 26.0% 16.0%, 36.1%
(82/620) (63/547) (19/73)
CAD 33.3% 29.6%, 37.0% 31.6% 27.7%, 35.5% 45.9% 34.6%, 57.3%
(206/618) (172/544) (34/74)
Number of risk factors
0 7.8% 5.7%, 9.9% 8.2% 5.9%, 10.5% 5.3% 0.2%, 10.3%
(49/626) (45/550) (4/76)
1 13.9% 11.2%, 16.6% 13.8% 10.9%, 16.7% 14.5% 6.6%, 22.4%
(87/626) (76/550) (11/76)
2 23.3% 20.0%, 26.6% 24.5% 20.9%, 28.1% 14.5% 6.6%, 22.4%
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Table 2 Summary of study population demographics, signs/symptoms, and risk factors (Continued)
(146/626) (135/550) (11/76)
3+ 55.0% 51.1%, 58.8% 53.5% 49.3%, 57.6% 65.8% 55.1%, 76.5%
(344/626) (294/550) (50/76)
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flow obstruction in this study.
Many patients with PAD are asymptomatic and are
not referred to vascular specialists when evaluated in the
primary care practice. These patients do not begin
prophylactic therapies, such as walking, as early as pos-
sible. Hirsch et al. found that only 11% of PAD patients
had symptoms of claudication [11]. The results of our
study suggest slightly higher rates of claudication in the
presence of PAD (25%); however, the majority of patients
in this group were asymptomatic. Given the increased
morbidity and mortality in asymptomatic PAD, specifically
without concomitant CAD, and the reported benefits of
early treatment, digital ABI could potentially provide early
detection and improved disease management [11]. The
medical literature indicates that abnormal ABI results are
highly concordant with angiographic diagnosis of PAD,
supporting the use of ABI or digital ABI in the primary
care setting as a more objective assessment of the need for
referral to a vascular specialist [24].
Given the severe primary and secondary consequences
of delayed diagnosis of PAD, early evaluation and detec-
tion is critical. While ABI measurement has long been
recognized as an acceptable means of evaluation, trad-
itional Doppler ABI may not be conducive to the primary
care setting because this method is time consuming and
requires specialized vascular technologists to be performedFigure 1 Prevalence of PAD by sex and age group in this
study population.properly [14]. Development of ABI devices that are easy to
use, inexpensive, accurate and less time-consuming can
potentially make PAD testing in the primary care practice
feasible. The FloChec™ measurement is performed in a few
minutes by a medical assistant under the direct supervision
of a primary care physician trained on the technique.
Previous studies have found that 46% of patients re-
ferred to vascular centers based on clinical suspicion alone
were without significant PAD [13]. Our study showed
similar results; 41% of patients with a result negative for
PAD had presented with at least one sign or symptom. As
supported by our research, a significant population pre-
sents with clinical symptoms or risk factors that may not
be attributable to PAD and who might not require referral
to a vascular specialist.
This study had several limitations. The registry was
designed to collect and describe digital ABI results and
patient history retrospectively, without pre-defined param-
eters. One major limitation was the lack of direct com-
parison to Doppler ABI/definitive diagnostic techniques
for each observation. Doppler ABI data was not captured
as part of the registry database, but is of primary import-
ance for currently ongoing and future studies evaluating
this new technology. The passive data collection method
used meant that not all data on demographics, signs/
symptoms, and risk factors could be collected for all pa-
tients. Of the observations provided, 8% had one or more
missing data field. All analyses were based on the number
of fields completed for each variable of interest.
This was an open data registry; therefore, the clinical
sites that provided data did so voluntarily. The variationTable 3 Unadjusted prevalence odds ratios (PAD positive
group compared to PAD negative group)
Measure OR (95% CI) P-value
Age 1.01 (0.99, 1.03) 0.391
Male 1.54 (0.92, 2.58) 0.099
Claudication 1.36 (0.76, 2.42) 0.295
Discolored/blue legs 1.52 (0.88, 2.63) 0.131
Non-healing wound 1.37 (0.69, 2.74) 0.372
High cholesterol 1.01 (0.61, 1.67) 0.975
Hypertension 0.84 (0.49, 1.44) 0.530
Diabetes 1.32 (0.81, 2.14) 0.266
Smoking history 1.63 (1.00, 2.64) 0.049
Stroke/TIA 2.70 (1.51, 4.85) <.001
CAD 1.84 (1.12, 3.01) 0.015
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in “real world” settings, where a wide variety of patients
were tested with the device. As a consequence of this
pragmatic approach, the data collection process did not
include additional controls or data monitoring. Risks of
this method included missing data and possible errors
during case report form completion. No inclusion or ex-
clusion criteria were applied; therefore, the data set may
be biased in either direction. However, given the large
number of patients tested and prevalence rates similar
to other studies, the risk of patient selection bias is low.
Lastly, this study lacked follow up or definitive diagnos-
tics; therefore, this study does not address sensitivity and
specificity of the digital ABI test. Although the results
are consistent with previous population-based studies;
additional studies are warranted to fully evaluate this
technology.
Conclusions
The results of this large, population-based study support
the use of a digital ABI device (FloChec™) using blood
volume plethysmography technology for early evaluation
and detection of patients at risk for PAD. Compared to
Doppler ABI, digital ABI devices enable PAD evaluation
in primary care settings and may allow for earlier detec-
tion of the disease. Of importance, the Medicare popula-
tion (over 65 years of age) may benefit most from early
evaluation with digital ABI in primary care settings. Fur-
ther studies are needed to determine the benefit to other
high risk populations, such as diabetics, and to evaluate
the correlation of digital ABI results using this device
with definitive diagnostic techniques.
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